First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Karen A AutioCelestia S HiganoLuke NordquistLeonard J ApplemanTian ZhangXin-Hua ZhuHani BabikerNicholas J VogelzangSandip M PrasadMichael T SchweizerRavi A MadanStephane BillotteNora CavazosOrlaith BoggRay LiKam ChanHelen ChoMegan KanedaI-Ming WangJenny ZhengSzu-Yu TangRobert HollingsworthKenneth A KernDaniel P PetrylakPublished in: Journal for immunotherapy of cancer (2023)
NCT02616185.